- Bone Health
- Immunology
- Hematology
- Respiratory
- Dermatology
- Diabetes
- Gastroenterology
- Neurology
- Oncology
- Ophthalmology
- Rare Disease
- Rheumatology
Dr Sang-Jin Pak Talks Biosimilar Market Stability
This week on the podcast, we’re speaking with Sang-Jin Pak, MD, the executive vice president of Samsung Bioepis’ Commercial Division.
In April 2020, Samsung Bioepis, in partnership with Merck, launched their trastuzumab biosimilar, Ontruzant, which has been on the market in Europe since 2018. This earlier release of biosimilars in Europe is common, as Europe has had a much easier time with biosimilar uptake than the United States, thanks to their decade-long head start in the industry. However, being ahead doesn’t necessarily mean everything runs smoothly. We sat down with Dr Sang-Jin Pak, the executive vice president of Samsung Bioepis’ Commercial Division, to discuss if the European way is the best way.
To learn more about Samsung Bioepis, visit samsungbioepis.com.
How AI Can Help Address Cost-Related Nonadherence to Biologic, Biosimilar Treatment
March 9th 2025Despite saving billions, biosimilars still account for only a small share of the biologics market—what's standing in the way of broader adoption and how can artificial intelligence (AI) help change that?
Biosimilars in Action: Market Shifts, Legal Insights, and FDA Approvals
February 9th 2025In this episode of Not So Different, host Skylar Jeremias covers the latest biosimilar developments, including new FDA approvals, patent disputes, and biosimilar market trends shaping the health care landscape.
Biosimilars Policy Roundup for March 2023—Podcast Edition
April 2nd 2023On this episode of Not So Different, we discuss some of the global biosimilar policy news that came out during the month of March, including a new bill in Congress and 2 Canadian jurisdictions implementing switching policies.
Biosimilars Gastroenterology Roundup for February 2023—Podcast Edition
March 5th 2023On this episode of Not So Different, we chronicle the latest gastroenterology news from February, including several updates on adalimumab and infliximab biosimilars and industry analyses on the utilization of these drugs and patient confidence in gastroenterologists’ recommendations.
